• No results found

Characterisation of linear predictability and non stationarity of subcutaneous glucose profiles

N/A
N/A
Protected

Academic year: 2020

Share "Characterisation of linear predictability and non stationarity of subcutaneous glucose profiles"

Copied!
24
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

TABLE 1. Biometric indices, treatment regimens, hba1c values and corresponding
Fig. 1. Box plots of (a) standard deviation values, (b) ACF decay exponents, , and DFA indices
Fig. 2. ACF for (a) a diabetic patient (profile 11) and for (b) a person without diabetes (profile
Fig. 4. The glucose time series are shown for profile 8 (a) and profile 15 (b) of type 2 diabetes

References

Related documents

An institutional theory is considered relevant in this study because it illustrates how socio-cultural challenges from the perspective of regulatory, normative and cognitive

To obtain antibodies with which to study MSP-7 biosynthesis, GST-fusion proteins were produced using bacterial expression systems, and used to immunise mice,

The speculative role of phototherapy as an external trigger for this drug- related adverse event should be confirmed in other cases by thorough study of the serotonin

An ideal external reporting system would have the fol- lowing core features 2 : centralized collection, colla- tion, and expert analysis of reports of errors, near- misses

Concern Worldwide Bangladesh engaged a review team to conduct the final evaluation of the five-year (Oct-Sept 2009) Municipal Health Partnership Program (MHPP) in seven

This paper has attempted an empirical investigation of how Armstrong (2012) tested the International Arbitrage Pricing Theory proposition that home currency movements affect the

The symbolic representation of the negative ternary inverter (NTI), positive ternary inverter (PTI) and standard ternary inverter (STI) is shown in fig.1.The three

For this reason our cost bene- fit analysis, comparing the potential costs of Lamivudine prophylaxis in 48 HBcAb positive HBsAg negative pa- tients treated with rituximab, and the